Pangaea Data launches an AI platform to enhance guideline adherence and reduce global healthcare strain. The new solution unifies Pangaea’s proven AI capabilities into one platform that seamlessly integrates with existing clinical systems and workflows.
South San Francisco, CA, USA; London, UK; October 21 — AI health innovator Pangaea Data has unveiled its next-generation platform designed to help clinicians close care gaps, identify untreated or sub-optimally treated patients, and enhance patient outcomes while reducing costs and increasing health system efficiency.
The platform emulates clinical reasoning to detect care gaps, identify missed or undertreated patients, automate follow-ups, and review records at scale — just as a clinician would.
Already deployed across health systems in 13 countries, Pangaea’s technology supports conditions such as Chronic Kidney Disease (CKD), Chronic Obstructive Pulmonary Disease (COPD), Asthma, Breast Cancer, Cancer Cachexia, Systemic Lupus Erythematosus (SLE), and Hypophosphatasia (HPP).
Pangaea is also collaborating with leading global partners, including AstraZeneca’s Alexion and digital health company Topcon, to advance early diagnosis and optimize treatment pathways worldwide.
Clinical reasoning, at scale
Designed to mirror clinical thinking, Pangaea’s platform reviews patient interactions and medical records like a clinician — but with the speed and reach of AI. It interprets both structured and unstructured data to uncover missed diagnoses, delayed treatments, incomplete referrals, and other hidden care gaps, even when the information exists within patient records.
Powered by advanced AI, the platform not only analyzes available data but also reasons through it to identify care that falls short of clinical guidelines. It integrates effortlessly with ambient listening tools to capture insights from real-time consultations and can recommend or automate next steps, such as scheduling follow-ups — enabling clinicians to act proactively without extra administrative work.
By surfacing guideline-based insights, the platform supports earlier interventions, enhancing patient outcomes and overall care quality.
“We go beyond data — we bring each patient’s story to life,” said Dr. Vibhor Gupta, Founder and CEO of Pangaea Data. “At-risk patients often already have the relevant data in their records, but what’s been missing is a system that sees the full picture and delivers timely, actionable insights. By focusing on what matters most, exactly when it matters, Pangaea helps clinicians act with precision, avoid alert fatigue, and improve care without increasing workload.”
Designed to work where care happens
Pangaea’s platform integrates seamlessly with existing electronic health record (EHR) systems, scheduling tools, and referral workflows, allowing clinicians to see insights on care gaps within the context of a patient’s journey. This eliminates the need to switch between systems or manage separate dashboards, enabling healthcare providers to act securely and close gaps without disrupting care.
A win-win for all
Health systems can adopt Pangaea’s platform with minimal financial risk, thanks to collaborations with pharmaceutical sponsors across multiple conditions, providing a low-cost entry point. This partnership model allows health systems to leverage real-time AI both at the point of care and for population health management.
Pangaea’s platform is already in use across prevalent and rare conditions, including Chronic Kidney Disease (CKD), Chronic Obstructive Pulmonary Disease (COPD), Cancer Cachexia, and rare diseases like Hypophosphatasia (HPP). It has proven highly effective at identifying untreated or sub-optimally treated patients. For instance, it detected CKD patients at risk with 97% sensitivity and 85% precision, and COPD patients at high risk of exacerbations with 99% sensitivity and 85% precision.
In cancer cachexia, the platform identified six times more undiagnosed patients who were missing appropriate treatments, despite relevant data being in their records. This early detection has helped reduce treatment costs per patient from £10,000 to £5,000, while enabling faster referrals, smoother pre-authorizations, and quicker treatment initiation — reducing the healthcare burden and improving patient outcomes.
Pangaea will showcase its platform at the ESMO Conference in Berlin (October 18–19) and HLTH USA 2025 in Las Vegas (October 19–22). Expanded functionality and new features are expected to launch in late 2025 and early 2026.
About Pangaea Data:
Pangaea Data, based in South San Francisco and London, offers an AI-driven platform deployed across health systems in 13 countries to help clinicians close care gaps. By identifying untreated or under-treated patients who are overlooked despite relevant data in their medical records, the platform ensures timely, guideline-concordant care. It also supports sustainable, privacy-compliant collaborations between health systems and pharmaceutical companies. Pangaea’s platform has demonstrated improved patient outcomes, reduced costs through early diagnosis and effective triaging, and increased revenues via optimized pre-authorizations and treatments.
The platform is designed to run on a health system’s infrastructure behind its firewall, ensuring full privacy compliance. It integrates seamlessly with existing electronic health records (EHRs), ambient listening tools, and scheduling systems, avoiding disruption to clinical or IT workflows.
Pangaea Data was founded by Dr. Vibhor Gupta and Prof. Yike Guo, who collectively bring over 20 years of academic and industry experience and have secured more than $300 million in academic research funding. Their advisors and investors include industry leaders such as Lord David Prior (Former Chairman, NHS England) and Mr. Andy Palmer (Former Head of Systems Integration, Novartis).
For more information, visit www.pangaeadata.ai
